Colon cancer antigen panel
AssigneesLudwig Institute for Cancer Research, Cornell Research Foundation, Inc.
InventorsYao-Tseng Chen, Lloyd J. Old, Matthew J. Scanlan, Elisabeth Stockert
Life of this patent
Estimating the term…
Abstract
The invention provides methods for diagnosing cancer including colon cancer, based on the identification of certain colon cancer-associated polypeptides as antigens that elicit immune responses in colon cancer. The identified antigens can be utilized as markers for diagnosing colon cancer, and for following the course of treatment of colon cancer.
Claims154
A method for diagnosing colon cancer in a subject comprising:
- obtaining a biological sample from a subject,
- contacting the sample with at least two different colon cancer-associated polypeptides encoded by nucleic acid molecules comprising a nucleotide sequence selected from the group consisting of SEQ ID NOs:1-15, and
- determining specific binding between the colon cancer-associated polypeptides and agents in the sample, wherein the presence of specific binding is diagnostic for colon cancer in the subject.
A method for diagnosing colon cancer in a subject comprising:
- obtaining a biological sample from a subject,
- contacting the sample with antibodies or antigen-binding fragments thereof, that bind specifically to at least two different colon cancer-associated polypeptides encoded by nucleic acid molecules comprising a nucleotide sequence selected from the group consisting of SEQ ID NOs:1-15, and
- determining specific binding between the antibodies or antigen-binding fragments thereof and colon cancer-associated polypeptides in the sample, wherein the presence of specific binding is diagnostic for colon cancer in the subject.
A method for determining onset, progression, or regression, of colon cancer in a subject, comprising:
- obtaining from a subject a first biological sample,
- contacting the first sample with at least two different colon cancer-associated polypeptides encoded by nucleic acid molecules comprising a nucleotide sequence selected form the group consisting of SEQ ID NOs:1-15,
- determining specific binding between agents in the first sample and the at least two different colon cancer-associated polypeptides,
- obtaining from a subject a second biological sample,
- contacting the second biological sample with at least two different colon cancer-associated polypeptides encoded by nucleic acid molecules comprising a nucleotide sequence selected form the group consisting of SEQ ID NOs:1-15,
- determining specific binding between agents in the second sample and the at least two different colon cancer-associated polypeptides, and
- comparing the determination of binding in the first sample to the determination of specific binding in the second sample as a determination of the onset, progression, or regression of the colon cancer.
A method for determining onset, progression, or regression, of colon cancer in a subject, comprising:
- obtaining from a subject a first biological sample,
- contacting the first sample with antibodies or antigen-binding fragments thereof, that bind specifically to at least two different colon cancer-associated polypeptides encoded by nucleic acid molecules comprising a nucleotide sequence selected from the group consisting of SEQ ID NOs:1-15,
- determining specific binding between colon cancer-associated polypeptides in the first sample and the antibodies or antigen-binding fragments thereof,
- obtaining from a subject a second biological sample, contacting the second sample with antibodies or antigen-binding fragments thereof, that bind specifically to at least two different colon cancer-associated polypeptides encoded by nucleic acid molecules comprising a nucleotide sequence selected from the group consisting of SEQ ID NOs:1-15,
- determining specific binding between colon cancer-associated polypeptides in the second sample and the antibodies or antigen-binding fragments thereof, and
- comparing the determination of specific binding in the first sample to the determination of specific binding in the second sample as a determination of the onset, progression, or regression of colon cancer.
A method for selecting a course of treatment of a subject having or suspected of having colon cancer, comprising:
- obtaining from the subject a biological sample,
- contacting the sample with at least two different colon cancer-associated polypeptides encoded by nucleic acid molecules comprising a nucleotide sequence selected from the group consisting of SEQ ID NOs:1-15,
- determining specific binding between agents in the sample that are differentially expressed in different types of cancer, and the colon cancer-associated polypeptides, and
- selecting a course of treatment appropriate to the cancer of the subject.
A method for selecting a course of treatment of a subject having or suspected of having colon cancer, comprising:
- obtaining from the subject a biological sample,
- contacting the sample with antibodies or antigen-binding fragments thereof that bind specifically to at least two different colon cancer-associated polypeptides encoded by nucleic acid molecules comprising a nucleotide sequence selected from the group consisting of SEQ ID NOs:1-15,
- determining specific binding between colon cancer-associated polypeptides in the sample that are differentially expressed in different types of cancer, and the antibodies or antigen-binding fragments thereof, and
- selecting a course of treatment appropriate to the cancer of the subject.
A kit for the diagnosis of colon cancer in a subject, comprising:
- at least two different colon cancer-associated polypeptides encoded by nucleic acid molecules comprising a nucleotide sequence selected from the group consisting of:
- SEQ ID NOs:1-15, one or more control antigens, and instructions for the use of the polypeptides in the diagnosis of colon cancer.
A kit for the diagnosis of colon cancer in a subject, comprising:
- antibodies or antigen-binding fragments thereof that bind specifically to at least two different colon cancer-associated polypeptides encoded by nucleic acid molecules comprising a nucleotide sequence selected from the group consisting of SEQ ID NOs:1-15, one or more control agents, and instructions for the use of the agents in the diagnosis of colon cancer.
A protein microarray comprising at least two different colon cancer-associated polypeptides, wherein the colon cancer-associated polypeptides are encoded by nucleic acid molecules comprising a nucleotide sequence selected from the group consisting of:
- SEQ ID NOs:1-15, fixed to a solid substrate.
A protein microarray comprising antibodies or antigen-binding fragments thereof, that specifically bind at least two different colon cancer-associated polypeptides encoded by nucleic acid molecules comprising a nucleotide sequence selected from the group consisting of:
- SEQ ID NOs:1-15, fixed to a solid substrate.
A nucleic acid microarray comprising at least two nucleic acids selected from the group consisting of SEQ ID NOs:1-15, fixed to a solid substrate.
A method for diagnosing colon cancer in a subject comprising:
- obtaining from the subject a biological sample, and
- determining the expression of at least two colon cancer-associated nucleic acid molecules or expression products thereof in the sample, wherein the nucleic acid molecules comprise a nucleotide sequence selected from the group consisting of:
- SEQ ID NO:
- 1-15, wherein the expression is diagnosis of the colon cancer in the subject.
A method for determining onset, progression, or regression, of colon cancer in a subject comprising:
- obtaining from a subject a first biological sample,
- determining a level of expression of at least two colon cancer-associated nucleic acid molecules or expression products thereof in the first sample, wherein the nucleic acid molecules are selected from the group consisting of:
- SEQ ID NOs:
- 1-15,
- obtaining from the subject a second biological sample,
- determining a level of expression of at least two colon cancer-associated nucleic acid molecules or expression products thereof in the second sample, wherein the nucleic acid molecules are selected from the group consisting of:
- SEQ ID NOs:
- 1-15, and
- comparing the level of expression in the first sample to the level of expression in the second sample as a determination of the onset, progression, or regression of the colon cancer.
A method for diagnosing cancer in a subject comprising:
- obtaining a biological sample from a subject,
- contacting the sample with a colon cancer-associated polypeptide encoded by a nucleic acid molecule comprising a nucleotide sequence selected from the group consisting of SEQ ID NOs:1, 2, 5, and 6, and
- determining specific binding between the colon cancer-associated polypeptide and agents in the sample, wherein the presence of specific binding is diagnostic for cancer in the subject.
A method for diagnosing cancer in a subject comprising:
- obtaining a biological sample from a subject,
- contacting the sample with an antibody or antigen-binding fragment thereof, that binds specifically to a colon cancer-associated polypeptide encoded by a nucleic acid molecule comprising a nucleotide sequence selected from the group consisting of SEQ ID NOs:1, 2, 5, and 6, and
- determining specific binding between the antibody or antigen-binding fragment thereof and the colon cancer-associated polypeptide in the sample, wherein the presence of specific binding is diagnostic for cancer in the subject.
A method for determining onset, progression, or regression, of cancer in a subject, comprising:
- obtaining from a subject a first biological sample,
- contacting the first sample with a colon cancer associated polypeptide encoded by a nucleic acid molecule comprising a nucleotide sequence selected from the group consisting of SEQ ID NOs:1, 2, 5, and 6,
- determining specific binding between agents in the first sample and the colon cancer-associated,
- obtaining from a subject a second biological sample,
- contacting the second sample with a colon cancer associated polypeptide encoded by a nucleic acid molecule comprising a nucleotide sequence selected from the group consisting of SEQ ID NOs:1, 2, 5, and 6,
- determining specific binding between agents in the second sample and the colon cancer-associated polypeptide, and
- comparing the determination of binding in the first sample to the determination of specific binding in the second sample as a determination of the onset, progression, or regression of cancer.
A method for determining onset, progression, or regression, of cancer in a subject, comprising:
- obtaining from a subject a first biological sample,
- contacting the first sample with antibodies or antigen-binding fragments thereof, that bind specifically to a colon cancer-associated polypeptides encoded by a nucleic acid molecule comprising a nucleotide sequence selected from the group consisting of SEQ ID NOs:1, 2, 5, and 6,
- determining specific binding between colon cancer-associated polypeptides in the first sample and the antibodies or antigen-fragments thereof,
- obtaining from a subject a second biological sample,
- contacting the second sample with antibodies or antigen-binding fragments thereof, that bind specifically to a colon cancer-associated polypeptides encoded by a nucleic acid molecule comprising a nucleotide sequence selected from the group consisting of SEQ ID NOs:1, 2, 5, and 6,
- determining specific binding between colon cancer-associated polypeptides in the second sample and the antibodies or antigen-binding fragments thereof, and
- comparing the determination of specific binding in the first sample to the determination of specific binding in the second sample as a determination of the onset, progression, or regression of cancer.
A method for selecting a course of treatment of a subject having or suspected of having cancer, comprising:
- obtaining from the subject a biological sample,
- contacting the sample with a colon cancer-associated polypeptide encoded by a nucleic acid molecule comprising a nucleotide sequence selected from the group consisting of SEQ ID NOs:1, 2, 5, and 6,
- determining specific binding between agents in the sample that are differentially expressed in different types of cancer, and the colon cancer-associated polypeptide, and
- selecting a course of treatment appropriate to the cancer of the subject.
A method for selecting a course of treatment of a subject having or suspected of having cancer, comprising:
- obtaining from the subject a biological sample,
- contacting the sample with antibodies or antigen-binding fragments thereof that bind specifically to a colon cancer-associated polypeptide encoded by a nucleic acid molecule comprising a nucleotide sequence selected from the group consisting of SEQ ID NOs:1, 2, 5, and 6,
- determining specific binding between colon cancer-associated polypeptides in the sample that are differentially expressed in different types of cancer, and the antibodies or antigen-binding fragments thereof, and
- selecting a course of treatment appropriate to the cancer of the subject.
A kit for the diagnosis of cancer in a subject, comprising:
- a colon cancer-associated polypeptide encoded by a nucleic acid molecule comprising a nucleotide sequence selected from the group consisting of:
- SEQ ID NOs:
- 1, 2, 5, and 6;
- one or more control antigens;
- and instructions for the use of the polypeptide and control antigens in the diagnosis of cancer.
A kit for the diagnosis of cancer in a subject, comprising:
- antibodies or antigen-binding fragments thereof that bind specifically to a colon cancer-associated polypeptide encoded by a nucleic acid molecule comprising a nucleotide sequence selected from the group consisting of SEQ ID NOs:1, 2, 5, and 6;
- one or more control agents;
- and instructions for the use of the antibodies, antigen-binding fragments, and agents in the diagnosis of cancer.
A protein microarray comprising a colon cancer-associated polypeptide, wherein the colon cancer-associated polypeptide is encoded by a nucleic acid molecule comprising a nucleotide sequence selected from the group consisting of:
- SEQ ID NOs:
- 1, 2, 5, and 6, fixed to a solid substrate.
A protein microarray comprising antibodies or antigen-binding fragments thereof, that specifically bind a colon cancer-associated polypeptide encoded by a nucleic acid molecule comprising a nucleotide sequence selected from the group consisting of:
- SEQ ID NOs:1, 2, 5, and 6, fixed to a solid substrate.
A nucleic acid microarray comprising a nucleic acid selected from the group consisting of SEQ ID NOs:
- 1, 2, 5, and 6, fixed to a solid substrate.
A method for diagnosing cancer in a subject comprising:
- obtaining from the subject a biological sample, and
- determining the expression of a colon cancer-associated nucleic acid molecule or expression product thereof in the sample, wherein the nucleic acid molecule comprises a nucleotide sequence selected from the group consisting of:
- SEQ ID NO:
- 1, 2, 5, and 6, wherein the expression is diagnostic of cancer in the subject.
A method for determining onset, progression, or regression, of cancer in a subject comprising:
- obtaining from a subject a first biological sample,
- determining a level of expression of a colon cancer-associated nucleic acid molecule or expression products thereof in the first sample, wherein the nucleic acid molecule is selected from the group consisting of:
- SEQ ID NOs:
- 1, 2, 5, and 6,
- obtaining from the subject a second biological sample,
- determining a level of expression of a colon cancer-associated nucleic acid molecule or expression product thereof in the second sample, wherein the nucleic acid molecule is selected from the group consisting of:
- SEQ ID NOs:
- 1, 2, 5, and 6, and
- comparing the level of expression in the first sample to the level of expression in the second sample as a determination of the onset, progression, or regression of the cancer.
Dependencies are inferred from the claim text.